Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND

Velde, A. Rogier van der; Meijers, Wouter C.; Heuvel, ER Edwin van den; Bakker, Stephan J. L.; Gilst, Wiek H. van; Harst, Pim van der; Hillege, Hans L.; Boer, Rudolf A. de

doi:10.1016/j.ijcard.2016.07.241

Cited by 10 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we found no associations between high HbA1c and galectin-3, indicating that they are two independent biomarkers associated with depression. Our results differ from previous research as we did not find any associations between high galectin-3 and age, hypertension, hypercholesterolemia, triglycerides, s-LDL, BMI, s-creatinine or smoking ( 19 , 21 , 22 , 23 ). In none of these previous studies had the results been controlled for depression, the results might have been different if they had.…”

Section: Discussioncontrasting

confidence: 99%

“…In Alzheimer’s disease, increased levels of serum galectin-3 have been demonstrated ( 15 ). Significant associations have previously been found between galectin-3 and age, sex, type 2 diabetes mellitus, hypertension, hypercholesterolemia, triglycerides, LDL, BMI, renal dysfunction and smoking ( 19 , 21 , 22 , 23 ). Metformin in type 2 diabetes mellitus has, however, been linked to lower galectin-3 levels ( 22 ).…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Depression in type 1 diabetes was associated with high levels of circulating galectin-3

Melin

Dereke

Thunander

et al. 2018

Endocrine Connections

View full text Add to dashboard Cite

ObjectiveNeuroinflammatory responses are implicated in depression. The aim was to explore whether depression in patients with type 1 diabetes (T1D) was associated with high circulating galectin-3, controlling for metabolic variables, s-creatinine, life style factors, medication and cardiovascular complications.DesignCross-sectional.MethodsParticipants were T1D patients (n = 283, 56% men, age 18–59 years, diabetes duration ≥1 year). Depression was assessed by Hospital Anxiety and Depression Scale-depression subscale. Blood samples, anthropometrics and blood pressure were collected, and supplemented with data from medical records and the Swedish National Diabetes Registry. Galectin-3 ≥2.562 µg/l, corresponding to the 85th percentile, was defined as high galectin-3.ResultsMedian (quartile1, quartile3) galectin-3 (µg/l) was 1.3 (0.8, 2.9) for the 30 depressed patients, and 0.9 (0.5, 1.6) for the 253 non-depressed, P = 0.009. Depression was associated with high galectin-3 in all the 283 patients (adjusted odds ratio (AOR) 3.5), in the 161 men (AOR 3.4), and in the 122 women (AOR 3.9). HbA1c, s-lipids, s-creatinine, blood pressure, obesity, smoking, physical inactivity, cardiovascular complications and drugs (antihypertensive, lipid lowering, oral antidiabetic drugs and antidepressants) were not associated with high galectin-3.ConclusionsThis is the first study to show an association between depression and galectin-3. Depression was the only explored parameter associated with high circulating galectin-3 levels in 283 T1D patients. High galectin-3 levels might contribute to the increased risk for Alzheimer’s disease, cardiovascular and all-cause mortality observed in persons with depression. Potentially, in the future, treatment targeting galactin-3 might improve the prognosis for patients with high galectin-3 levels.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 95%

Depression in type 1 diabetes was associated with high levels of circulating galectin-3

Melin

Dereke

Thunander

et al. 2018

Endocrine Connections

View full text Add to dashboard Cite

show abstract

“…Clinical correlates of change in Gal-3 in our study are in keeping with two prior studies examining temporal changes in Gal-3 levels: Among patients with existing HF, Anand, et al found that lower baseline Gal-3 levels, lower eGFR, interim decrease in eGFR, female sex, and higher BMI were associated with greater increases in Gal-3 levels at 4 months (19). Similarly, in the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) study, investigators showed that in general population, systolic blood pressure >170 mmHg and urinary albumin excretion >30 mg/24 h were independent predictors of dynamic increase in Gal-3 levels across a time span of 9 years (17). We validate hypertension as a predictor, but extend these findings by showing that diabetes and obesity are also associated with a rise in Gal-3 over the span of about a decade.…”

Section: Discussionmentioning

confidence: 99%

“…Despite relatively low biological variation (14), plasma Gal-3 levels do change over time (15) and Gal-3 trajectory might be independent of baseline levels (16). Systolic blood pressure and urinary excretion of albumin were shown to predict temporal changes in Gal-3 levels (17). Prior studies have shown that serial measurements of Gal-3 provides incremental prognostic information in patients with existing HF (8,18,19).…”

Section: Introductionmentioning

confidence: 99%

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes

Ghorbani

Bhambhani

Christenson

et al. 2018

Journal of the American College of Cardiology

Self Cite

View full text Add to dashboard Cite

Background Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear. Objectives We sought to study clinical determinants of change in Gal-3 among communitydwelling individuals. Further, we sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD) and mortality. Methods A total of 2,477 participants of the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at two exams (1995-1998 and 2005-2008). Linear regression was used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3. Results The following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female gender, hypertension, diabetes, body-mass index, interim development of chronic kidney disease and HF (P<0.0001 for all in multivariable- model). Change in Gal-3 was associated with future HF (HR 1.39 per 1-SD increase, 95%CI 1.13-1.71), CVD (HR 1.29, 95%CI 1.11-1.51), and all-cause mortality (HR 1.30 95%CI 1.17-1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (P<0.05 for both). Conclusions Longitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention.

show abstract

“…It is interesting to note that, although NT-proBNP and troponin were shown to be predictive for incident HF in the general population, the predictive value of sST2, Gal3, and other non-cardiac-specific markers is limited and some sex-specific differences have been observed [90,121]. Interestingly, longitudinal changes in Gal-3 concentrations appear to have stronger predictive value for future cardiovascular diseases as compared to single measurements [122,123]. Thus, sequential biomarker analysis may provide better resolutions in subclinical populations.…”

Section: Non-cardiac-specific Plasma Biomarkers In Subclinical Heart Diseasementioning

confidence: 99%

The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies

Stege

Boer

Berg

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

For patients with hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) or arrhythmogenic cardiomyopathy (ACM), screening for pathogenic variants has become standard clinical practice. Genetic cascade screening also allows the identification of relatives that carry the same mutation as the proband, but disease onset and severity in mutation carriers often remains uncertain. Early detection of disease onset may allow timely treatment before irreversible changes are present. Although plasma biomarkers may aid in the prediction of disease onset, monitoring relies predominantly on identifying early clinical symptoms, on imaging techniques like echocardiography (Echo) and cardiac magnetic resonance imaging (CMR), and on (ambulatory) electrocardiography (electrocardiograms (ECGs)). In contrast to most other cardiac diseases, which are explained by a combination of risk factors and comorbidities, genetic cardiomyopathies have a clear primary genetically defined cardiac background. Cardiomyopathy cohorts could therefore have excellent value in biomarker studies and in distinguishing biomarkers related to the primary cardiac disease from those related to extracardiac, secondary organ dysfunction. Despite this advantage, biomarker investigations in cardiomyopathies are still limited, most likely due to the limited number of carriers in the past. Here, we discuss not only the potential use of established plasma biomarkers, including natriuretic peptides and troponins, but also the use of novel biomarkers, such as cardiac autoantibodies in genetic cardiomyopathy, and discuss how we can gauge biomarker studies in cardiomyopathy cohorts for heart failure at large.

show abstract

Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND

Cited by 10 publications

References 39 publications

Depression in type 1 diabetes was associated with high levels of circulating galectin-3

Depression in type 1 diabetes was associated with high levels of circulating galectin-3

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes

The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies

Contact Info

Product

Resources

About